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Abstract
Introduction: The gene expression profiles of cancer cells are closely related to their aggressiveness and
metastatic potential. Antibody-based immunohistochemistry (IHC) of tissue specimens is a common method of
identifying expressed proteins in cancer cells and increasingly inform treatment decisions. Molecular imaging is a
potential method of performing similar IHC studies in vivo without the requirement for biopsy or tumor excision.
To date, antibody-based imaging has been limited by high background levels related to slow clearance, making
such imaging practical. However, optically activatable imaging agents, which are only fluorescent when bound to
their cognate receptor, open the possibility of doing in vivo multi-color IHC.
Methods: We describe the use of activatable, near infrared fluorescence-labeled AlexaFluor680 (Alexa680)
conjugated panitumumab (Pan) targeted against human epidermal growth factor receptor (EGFR) (Pan-Alexa680)
and Indocyanine Green (ICG) conjugated trastuzumab (Tra) targeted against human epidermal growth factor
receptor type 2 (HER2) (Tra-ICG) were synthesized and evaluated in cells in vitro and in an orthotopic breast cancer
mouse model in vivo.
Results: Pan-Alexa680 (self-quenched; SQ) and Tra-ICG were initially quenched but demonstrated a 5.2- and 50-
fold dequenching capacity under detergent treatment, respectively. In vitro microscopy and flow cytometry using
MDA-MB-468 (EGFR+/HER2-) and 3T3/HER2 cells (EGFR-/HER2+), demonstrated specific fluorescence signal for each
cell type based on binding to Pan-Alexa680(SQ) or Tra-ICG. An in vivo imaging study employing a cocktail of Pan-
Alexa680(SQ) and Tra-ICG (each 50 μg) was injected into mice with orthotopic MDA-MB-468 and 3T3/HER2 tumors
in the breast. Each probe visualized only the target-specific breast tumor.
Conclusions: Multi-color target-specific fluorescence breast cancer imaging can be achieved in vivo by employing
two activatable fluorescent probes administered as a cocktail. The images allowed us to see a specific receptor
expression in each breast tumor without post-image processing.
Introduction
Antibodies are macromolecules with high binding speci-
ficity for target antigens. This makes them excellent
scaffolds for molecular imaging probes. However, a cen-
tral limitation of using antibodies for imaging is that
they are slow to clear from the body resulting in non-
specific background contamination, reducing the target-
to-background ratio. In order to overcome the high
background signal found with labeled intact antibodies,
labeled antibody fragments, which show more rapid
clearance, have been developed. However, faster clear-
ance from the blood pool leads to lower concentrations
and, therefore, lower tumor uptake [1].
Optical imaging has many theoretical advantages for
tumor identification and characterization. A central advan-
tage is that simultaneous multi-color imaging can be
employed to characterize expression profiles [2,3]. By
using two or more different antibodies labeled with dis-
tinct colors, unbound antibody in the normal tissue can be
mathematically subtracted [4,5], since the bio-distribution
of antibodies is similar in normal organs and only differs
markedly at the tissue expressing the target antigen.
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However, this approach is somewhat inefficient as it sub-
tracts the target signal as well as the background signal.
Therefore, another approach to reducing background sig-
nal from two-antibody-based optical is to take advantage
of the unique feature of fluorescence that allows it to be
quenched or activated depending on its chemical state.
Such activatable probes (for example, labeled antibodies)
are designed to generate signal only after being bound and
processed by the target cancer cells; therefore, high accu-
mulation of antibodies in the target tissue can be clearly
visualized while the background signal remains quenched
[6,7]. This approach permits many high tumor-to-back-
ground ratios to be achieved [8].
In this study, two different antibodies against human
epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor type 2 (HER2) were
conjugated with activatable near-infrared (NIR) fluoro-
phores, namely Indocyanine Green (ICG) and Alexa-
Fluor680 (Alexa680), which emit light at different
wavelengths. We then employed these two activatable
antibodies as a cocktail in mice with EGFR and HER2




Panitumumab (Pan), a fully human IgG2 monoclonal
antibody (mAb) directed against the extracellular
domain of the human EGFR (HER1), was purchased
from Amgen (Thousand Oaks, CA, USA). Trastuzumab
(Tra), a recombinant humanized mAb directed against
the human HER2, was purchased from Genentech Inc.
(South San Francisco, CA, USA). ICG-Sulfo-OSu was
purchased from Dojindo Molecular Technologies (Rock-
ville, MD, USA). Alexa680-NHS ester was purchased
from Invitrogen Co. (Carlsbad, CA, USA). All other che-
micals used were of reagent grade.
Synthesis of Alexa680 or ICG conjugated antibodies
Panitumumab (0.5 mg, 3.4 nmol) was incubated with
Alexa680-NHS ester (39.3 μg, 34 nmol) in 0.1 M
Na2HPO4 (pH 8.6) at room temperature for one hour,
followed by the purification with a size exclusion column
(PD-10; GE Healthcare, Piscataway, NJ, USA). ICG label-
ing of trastuzumab was also performed by reacting mAb
with ICG at a ratio of 1:6 in the same manner as Pan-
Alexa680. The concentrations of Alexa680 and ICG were
calculated by measuring the absorption with the UV-Vis
system (8453 Value UV-Vis system; Agilent Technolo-
gies, Santa Clara, CA, USA) to confirm the number of
fluorophore molecules conjugated with each antibody
molecule. The protein concentration was also determined
by measuring the absorption at 280 nm with a UV-Vis
system. The number of Alexa680 and ICG per antibody
was adjusted to approximately 4.0 to 4.5 and 0.7 to 1.0,
respectively. As a comparison, Pan conjugated with
approximately one Alexa680 (always-on type; Pan-
Alexa680 (ON)) was also synthesized.
Determination of quenching capacity in vitro
The quenching abilities of each conjugate were investi-
gated by denaturing them with 1% SDS as described pre-
viously [9]. Briefly, the conjugates were incubated with
1% sodium dodecyl sulfate (SDS) in PBS for 15 minutes
at room temperature. As a control, the samples were
incubated in PBS. The fluorescence signal intensity of
Pan-Alexa680 was measured with a fluorescence spectro-
meter (Perkin-Elmer LS55, Perkin-Elmer, Shelton, CT,
USA). The change in fluorescence intensity of ICG was
investigated with an in vivo imaging system (Maestro,
CRi Inc., Woburn, MA, USA) using 710 to 760 nm exci-
tation and 800 nm long-pass emission filters.
Cell culture
The EGFR+/HER2- breast cancer cell line, MDA-MB-468,
and the EGFR-/HER2+ cell line, NIH/3T3 (3T3/HER2),
were used. Both cell lines were grown in RPMI 1640 (Life
Technologies, Gaithersburg, MD, USA) containing 10%
fetal bovine serum (Life Technologies), 0.03% L-glutamine,
100 units/mL penicillin, and 100 μg/mL streptomycin in
5% CO2 at 37°C.
Fluorescence microscopy studies
MDA-MB-468 cells or 3T3/HER2 cells (1 × 104) were pla-
ted on a covered glass-bottomed culture well and incu-
bated for 16 hours. Pan-Alexa680 (ON or self-quenched;
SQ) and Tra-ICG (10 μg/mL) were then added to MDA-
MB-468 cells and 3T3/HER2 cells, respectively. The cells
were incubated for either one or eight hours followed by
washing once with PBS, and fluorescence microscopy was
performed using an Olympus BX81 microscope (Olympus
America, Inc., Melville, NY, USA) equipped with the fol-
lowing filters: excitation wavelength 590 to 650 nm and
672.5 to 747.5 nm, emission wavelength 662.5 to 747.5 nm
and 765 to 855 nm for Alexa680 and ICG, respectively.
Transmitted light differential interference contrast images
were also acquired. To validate the specific binding of the
antibody, excess antibody (100 μg) was used to block
10 μg of dye-antibody conjugates.
Flow cytometry studies
Fluorescence signal from cells after incubation with Pan-
Alexa680 (ON, SQ) or Tra-ICG was measured using a
FACS Calibur flow cytometer (BD Biosciences, San Jose,
CA, USA) and CellQuest software (BD Biosciences).
Briefly, MDA-MB-468 and 3T3/HER2 cells (1 × 105) were
incubated with Pan-Alexa680 (ON or SQ) and Tra-ICG at
37°C for one or eight hours, respectively. To validate the
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specific binding of the antibody, excess antibody (50 μg)
was used to block 0.5 μg of dye-antibody conjugates.
Tumor model
All procedures were carried out in compliance with the
Guide for the Care and Use of Laboratory Animal
Resources (1996), National Research Council, and
approved by the National Cancer Institute Animal Care
and Use Committee. Six- to eight-week-old female homo-
zygote athymic nude mice were purchased from Charles
River (NCI-Frederick, Frederick, MD, USA). During the
procedure, mice were anesthetized with isoflurane. MDA-
MB-468 cells (2 × 106 cells) were injected subcutaneously
into the right mammary pads of the mice, and two weeks
later (because they grow faster), 3T3/HER2 cells (2 × 106
cells) were injected into the left mammary pads. The
experiments were conducted at six days after 3T3/HER2
cell injection.
In vivo two-color two-activatable imaging targeted for
EGFR and HER2
A mixture of Tra-ICG and Pan-Alexa680(SQ or ON)
(each 50 μg) was injected via the tail vein into tumor-
bearing mice (MDA-MB-468 and 3T3/HER2). The mice
were anesthetized with intraperitoneally administered 10%
sodium pentobarbital, and fluorescence images were
obtained for four days with a flurescence camera (Pearl
Imager LI-COR Biosciences using the 700 and 800 nm
fluorescence channel or Maestro in vivo Imaging System
CRi) using two filter sets). The red filter sets were used to
image Alexa680 fluorescence and the NIR filter sets were
used for ICG fluorescence. The red filter set uses a band-
pass filter, which ranges between 615 to 665 nm (excita-
tion) and a long-pass filter over 700 nm (emission); the
NIR filter set uses a band-pass filter from 710 to 760 nm
(excitation) and a long-pass filter over 800 nm (emission).
The tunable emission filter was automatically stepped in
10 nm increments from 650 to 950 nm for the red and
NIR filter sets at constant exposure. The spectral fluores-
cence images consist of autofluorescence spectra and the
spectra from Alexa680 and ICG, which were then
unmixed, based on their spectral patterns using commer-
cial software (Maestro software; CRi). Mice were sacrificed
with carbon dioxide immediately after in vivo imaging.
The tumors were excised and ex vivo imaging was per-
formed using Pearl Imager and Maestro in vivo imaging
system.
Statistical analysis
Quantitative data were expressed as mean ± SD. Means
were compared using two-way factorial ANOVA followed
by the Tukey-Kramer test. P-values of < 0.05 were consid-
ered statistically significant.
Results
Quenching capacity of dye conjugated antibody
The quenching capacities measured by adding 1% SDS
to dye-conjugated antibody were 50-, 5.2- and 1.2-fold
for Tra-ICG, Pan-Alexa680(SQ), and Pan-Alexa680
(ON), respectively.
In vitro fluorescent characterization of probes
In the microscopy studies (Figure 1), the fluorescence
signals from Pan-Alexa680(ON) and Pan-Alexa680(SQ)
were observed on the surface of MDA-MB-468 cells one
hour after incubation. Both probes also showed fluores-
cent signal within the cells eight hours after incubation,
and the fluorescent dots were brighter for Pan-Alexa680
(SQ) than for Pan-Alexa680(ON). These signals were
completely blocked by the addition of excess panitumu-
mab. Similarly, fluorescence signal from Tra-ICG was
observed within the 3T3/HER2 cells. While signal was
minimal at one hour after incubation because of greater
quenching magnitude of Tra-ICG than Pan-Alexa680,
many bright intracellular foci were present by eight
hours, and these signals were blocked by excess
trastuzumab.
FACS studies were similar to microscopy studies, that is,
Pan-Alexa680(ON, SQ) and Tra-ICG exhibited specific
binding to MDA-MB-468 and 3T3/HER2 cells, respec-
tively (Figure 2). Pan-Alexa680(SQ) showed progressively
brighter signal over time compared with Pan-Alexa680
(ON) where the signal was lower and constant.
In vivo two-color activatable imaging targeted for EGFR
and HER2
Figure 3A shows the images of tumor-bearing mice
(MDA-MB-468 and 3T3/HER2) injected with the mix-
ture of Pan-Alexa680(ON or SQ) and Tra-ICG, which
was obtained with the Pearl Imager. Pan-Alexa680(ON)
detected the targeted tumor (MDA-MB-468, EGFR+);
however, high background and non-specific tumor
uptake (3T3/HER2) are evident on Day 1 through Day 3
post injection. At Day 4, relatively selective images of
EGFR positive (MDA-MB-468) tumors were obtained. In
contrast, Pan-Alexa680(SQ) clearly visualized MDA-MB-
468 with high tumor-to-background ratios as early as
Day 2 and at all later time points, although a slight signal
was detected in the 3T3/HER2 tumor and bladder at Day
1. On the other hand, Tra-ICG specifically visualized the
HER2 positive 3T3/HER2 tumors, although slight fluor-
escent signals were noticed in the liver and intestine.
Tumor-to-background (non-targeted tumors, liver, and
neck) ratios were significantly higher (P < 0.01) for Pan-
Alexa680(SQ) compared with Pan-Alexa680(ON) for
four days (Figure 3B). Tumor-to-non-targeted tumor,
tumor-liver and tumor-neck ratios were 8.1, 10.3, and 8.8
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for Pan-Alexa680(SQ) at Day 4; whereas, they were 2.7,
3.9, and 4.5 for Pan-Alexa680(ON). In contrast, tumor-
to-background ratios with Tra-ICG were not significantly
different between the two groups (Figure 3C). The Maes-
tro spectral fluorescence imager provided similar images
to the Pearl imager (Figure 4). For instance, tumor-to-
non-targeted tumor, tumor-liver and tumor-neck were
8.1, 6.7, and 7.9 for Pan-Alexa680(SQ) at Day 4, whereas,
these same ratios were 2.8, 3.0, and 4.2 for Pan-Alexa680
(ON). Tumor-to-background ratios on Tra-ICG were not
significantly different between both groups.
Discussion
Activatable optical imaging using a labeled targeting anti-
body can be a sensitive and specific method of performing
in vivo molecular imaging with high tumor-to-background
ratios [6]. Like immunohistochemistry, each antibody can
be labeled with a different type of activatable fluorophore
allowing multi-color imaging. In this case, two different
EGFR receptors (EGFR and HER2) were targeted
successfully.
Activatable fluorescence probes can be based on one
of several mechanisms, including self-quenching
(Homo-FRET), auto-quenching (Hetero-FRET), H-dimer
formation, photo-induced electron transfer (PeT) and
uncaging [6]. Among these, self-quenching and auto-
quenching fluorophores are relatively easy to synthesize.
Both antibody conjugates showed intense bright fluores-
cence foci within tumor cells expressing the respective
targets, suggesting internalization of the antibody conju-
gate was required for activation [7,10].
In the case of the two activatable antibody conjugates
described here, Tra-ICG and Pan-Alexa680(SQ), we
showed that they could achieve impressive dequenching
ratios of 50- and 5.2-fold respectively. The difference of
dequenching capacity for ICG and Alexa680 can be
explained by distinct quenching mechanisms of two conju-
gates. The fluorescence of ICG can be quenched by auto-
quenching that is hetero-FRET between ICG and aromatic
amino acids of antibodies; in contrast, the fluorescence of
Alexa680 can be quenched by homo-FRET between two
or more Alexa680 molecules in a conjugate. Therefore,
greater numbers of Alexa680 on a single antibody could
achieve better quenching of Pan-Alexa680(SQ). However,
the bio-distribution was dramatically changed and showed
high uptake in the liver, when seven or more Alexa680s
were conjugated with a single panitumumab. Thus, the
number of Alexa680 molecules conjugated with a single
Figure 1 Fluorescence microscopy studies. MDA-MB-468 cells and 3T3/HER2 cells were incubated with Pan-Alexa680(ON or SQ) and Tra-ICG,
respectively, for one or eight hours. The higher fluorescent signals was detected by Pan-Alexa680(SQ) especially within the tumor cells
compared with Pan-Alexa680(ON) after eight hours incubation. Many bright foci could be detected by Tra-ICG at eight hours within the 3T3/
HER2 cells. These signals were completely blocked by the addition of excess panitumumab or trastuzumab.
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antibody had to be limited up to five despite of incomplete
self-quenching of Pan-Alexa(SQ). Therefore, fluorescence
signal of activated Pan-Alexa680(SQ) was greater; how-
ever, the dequenching ratios of Pan-Alexa(SQ) were lower
than that of Tra-ICG.
We employed two imaging devices in this study. The
Pearl imager (Pearl, LI-COR Biosciences) can detect two
kinds of NIR probes (emission wavelength 700 and 800
nm) separately by using optical filter sets and a highly
sensitive CCD camera. However, the multispectral fluor-
escence imager (Maestro, CRi) is equipped with a tunable
crystal filter that can distinguish between two or more
distinct fluorescence signals emanating from different
external and internal fluorophores by their spectral
separation [11]. The former system can simply show
photon counts at the specific range of wavelength, while
the latter system can extract the spectral signal from
each distinct fluorophores. As shown in the results,
spectral unmixing is able to separate the different colors
than optical filtering, allowing multi-targeted color
images with high tumor-to-background ratios.
In contrast to previous studies, which employed subcu-
taneous xenografts, we employed orthotopic bilateral
breast cancer tumor models, each one of which expressed
either EGFR or HER2. This enabled us to use the orthoto-
pic tumors as controls for each other [12]. A potential
alternative will be the use of fluorescent proteins, which
are excellent endogenous fluorescence emitters to be used
as a powerful tool for depicting various biological pro-
cesses both in vitro and in vivo [13]. However, for the
medical application, fluorescence proteins require in vivo
virus-mediated gene transfection [14,15], which is unlikely
to be permitted for the diagnosis in humans at least in the
near term.
Since tumors show genomic and proteomic diversity,
expression profiles vary widely even within a single
Figure 2 Flow cytometry studies. Flow cytometry studies showed specific binding of Pan-Alexa680(ON or SQ) and Tra-ICG to EGFR and HER2,
respectively. Pan-Alexa680(SQ) showed brighter signals and increased fluorescent signals over time compared with Pan-Alexa680(ON).
Sano et al. Breast Cancer Research 2012, 14:R61
http://breast-cancer-research.com/content/14/2/R61
Page 5 of 8
Figure 3 In vivo fluorescence imaging studies without post-image processing. (A) In vivo and ex vivo fluorescence images with mice
bearing 3T3/HER2 (left breast) and MDA-MB-468 (right breast) tumors using the Pearl imager which is based on filter sets. The mixture of Pan-
Alexa680(ON or SQ) and Tra-ICG was injected via the tail vein. Tra-ICG clearly visualized HER2 expressing 3T3/HER2 tumors. While Pan-Alexa680
(SQ) specifically detected EGFR expressing MDA-MB-468 tumors with higher contrast than Pan-Alexa680(ON). (B, C) The tumor to non-targeted
tumor, neck, and liver ratios for Alexa680 (B) or ICG (C) fluorescence intensity are displayed. Data are represented as mean ± s.d. (n = 4 mice).
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Figure 4 In vivo fluorescence imaging studies with post-image processing using the spectral separation. (A) In vivo and ex vivo
fluorescence images of mice bearing 3T3/HER2 (left breast) or MDA-MB-468 (right breast) tumors as depicted by the Maestro imager, which
employs an incremental filter and unmixing algorithms. The Alexa680 spectrum images shows a target specific image with Pan-Alexa680(SQ). In
contrast, high background signal was observed for Pan-Alexa680(ON). Tra-ICG clearly visualized HER2 expressing 3T3/HER2 tumors in both
groups. (B, C) The tumor to non-targeted tumor, neck and liver ratios for Alexa680 (B) or ICG (C) fluorescence intensity are depicted. Data are
represented as mean ± s.d. (n = 4 mice).
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lesion. EGFR and HER2 play an important role in carci-
nogenesis; overexpression of one or more members of
the EGFR family has been shown in a number of malig-
nancies, including breast, ovarian, non-small cell lung
cancer and squamous cell carcinomas. Furthermore,
high levels of expression relates to a poor prognosis
[16-18]. However, currently it is necessary to extract tis-
sue and stain using immunohistochemistry methods.
Detecting expression levels of EGFR profile in vivo
could be helpful for detecting and characterizing malig-
nant tumors, as well as determining therapy.
Conclusion
By employing two-color, activatable fluorophores conju-
gated to specific antibodies, multi-target specific fluores-
cence imaging could be achieved with high target-to-
background ratios that allowed us to see a specific
receptor expression in each breast tumor without post-
processing images. Such methods may be useful in the
future for in vivo characterization of breast cancers.
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